Journal profile · Medicine, Research & Experimental
Journal of Translational Medicine
ISSN 1479-5876 · BioMed Central · ENGLAND · Irregular · Founded 2003
Journal of Translational Medicine: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 9.66; fully open access; APC about USD 4,090; median 109 days to acceptance (178 articles, last 24 months); community-reported acceptance: about 50%; 1,581 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Translational Medicine is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Ferroptosis and cancer prognosis and Immunotherapy and Immune Responses, together about 24.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science. The journal covers all areas of translational medicine but also has several specialized sections: Cancer Metabolism Cancer Microenvironment Cardiovascular, Metabolic and Lipoprotein Translation Cell Death and Senescence Cell, Tissue and Gene Therapy Cellular Metabolism Therapy Clinical Translation Combination Strategies Computational Modelling and Epidemiology Data-driven Clinical Decision Processes Disease Biomarkers Emerging Therapeutics Fibrosis Hot Topics Illnesses of Unknown Etiology Immune RadioBiology Immunobiology and Immunotherapy ImmunoVirology and ImmunoOncology Medical Bioinformatics Molecular Pathology Nanobiomaterials & Nanomedicine Network Medicines Neuroscience Nutrition & Metabolism Pain, Critical Care and Anesthesia Patient-targeted Molecular Therapies Personalised Medicine Regenerative Medicine Reproductive Medicine & Clinical Reproductive Sciences Translational Cancer Biology Translational Craniofacial and Dental Medicine Translational Genomics and Genetics Translational Hematology Translational Imaging Translational Medicines ‘Ecosystem’ Translational Metagenomics Translational Ophthalmology Translational Process Translational Signaling and System Biology Please read the Sections' descriptions to know more about the journal's aims and scope.
From the journal's Aims & Scope
Research area (LetPub): Medicine, Research & Experimental
Editor-in-chief Francesco MarincolaPublisher website
Editorial board by country: 4 in mainland China (about 5%); most named United States 22, Italy 20, Qatar 11, United Kingdom 5, Mainland China 4 (82 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.7%
- Ferroptosis and cancer prognosisMedicine8%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.3%
- Immune cells in cancerImmunology and Microbiology6%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5%
- CAR-T cell therapy researchMedicine4.9%
- Gut microbiota and healthBiochemistry, Genetics and Molecular Biology4.8%
- Cancer Cells and MetastasisMedicine4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 9.66LetPub ·
- Impact factor (publisher) 2025
- 9.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 8.8Publisher website ·
- CiteScore 2026-06
- 11.3LetPub ·
- SJR 2026-06
- 2.41LetPub ·
- SNIP 2026-06
- 1.67LetPub ·
- h-index
- 87LetPub ·
- h-index
- 193OpenAlex ·
- i10-index
- 6,435OpenAlex ·
- 2-year mean citedness
- 8.26OpenAlex ·
- Self-citation rate
- 2.1%LetPub ·
- Share of gold OA articles
- 99.97%LetPub ·
Volume
- Articles per year
- 1,483LetPub ·
- Downloads per year (publisher) 2025
- 13,000,000Publisher website ·
Articles by year OpenAlex count · 10,721 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 1,413 | 1,413 | 842 |
| 2025 | 1,581 | 1,581 | 13,414 |
| 2024 | 1,173 | 1,173 | 20,146 |
| 2023 | 927 | 927 | 26,950 |
| 2022 | 631 | 631 | 21,545 |
| 2021 | 532 | 532 | 18,493 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
109 daysMedian, submission to acceptance · P25–P75 78 days – 150 days
- Acceptance to online
- median 14 days (178 articles)
- Submission to online
- median 131 days
- Sample
- 178 articles with submission and acceptance dates (3,279 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Submission to first decision
- 11 daysPublisher website ·
- Submission to publication (journal-reported)
- about 25 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,350 / USD 4,090 / GBP 3,050 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,890 / EUR 3,190 / GBP 2,890 | — | — | |
| LetPub | GBP 3,050 / USD 4,090 / EUR 3,350 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
- Mitochondrial Signalling and Impairment in Inflammation: Mechanism of Action on Cellular Homeostasis and PathogenesisDeadline
- Harnessing Innovative Machine Learning Techniques to Combat Drug Resistance in Solid TumorsDeadline
- Computational Modelling and Network Medicine in Drug Toxicology and Clinical PharmacovigilanceDeadline
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Irregular
- Founded
- 2003
- ISSN
- 1479-5876
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Translational Medicine
What CAS zone is Journal of Translational Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Translational Medicine is in Zone 2 of Medicine, and in Zone 2 of the minor category Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Translational Medicine?
The latest impact factor listed by LetPub is 9.66; CiteScore 11.3, h-index 193.
How long does peer review take at Journal of Translational Medicine?
Based on the dates recorded on 178 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 109 days (interquartile range 78–150 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Translational Medicine based?
Of the 82 board members whose country the journal's board page names, 4 (about 5%) are in mainland China; the countries named most often are United States (22), Italy (20) and Qatar (11). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Translational Medicine?
According to LetPub and DOAJ records, Journal of Translational Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Journal of Translational Medicine open access, and what is the APC?
Journal of Translational Medicine is a fully open-access journal. APC about USD 4,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .